Weed Have Doubled Risk For Psychosis, Bipolar Disorder” style=”width:100%;max-height:420px;object-fit:cover;border-radius:8px;display:block;” />#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
A longitudinal study examining adolescent cannabis use found that teenagers who use cannabis have approximately double the risk of developing psychosis and bipolar disorder compared to non-using peers, with risk appearing to increase with frequency and duration of use. The findings suggest that the developing adolescent brain may be particularly vulnerable to cannabis-induced psychiatric sequelae, potentially due to ongoing maturation of neural systems involved in emotion regulation and psychotic symptom threshold. These results have important implications for clinicians counseling adolescent patients and families about cannabis use, as they provide evidence that cannabis is not a benign recreational substance during this critical developmental window. The increased psychiatric risk persists even after accounting for potential confounding factors such as genetic predisposition and socioeconomic status, strengthening the causal inference. Clinicians should routinely screen adolescent patients for cannabis use during preventive care visits and discuss these specific psychiatric risks when providing substance use counseling, particularly for teenagers with family histories of psychotic or bipolar disorders. For young patients, the prudent clinical approach is to strongly discourage cannabis use during adolescence and defer any consideration of therapeutic cannabis until adulthood when brain development is complete and psychiatric risk may be substantially lower.
“What we’re seeing in the literature is that adolescent cannabis use, particularly with high-THC products, genuinely increases the risk for psychotic and mood disorders in vulnerable individuals, and as clinicians we have to take this seriously when counseling families and screening for family psychiatric history before any teen considers use.”
💊 While this study adds to growing evidence linking adolescent cannabis use to serious psychiatric outcomes, clinicians should recognize that the association likely reflects complex causality rather than simple linear risk. Genetic vulnerability, underlying prodromal symptoms, timing of use relative to critical developmental windows, potency and frequency of products used, and unmeasured confounders all contribute to heterogeneous outcomes, meaning not all adolescent users will develop psychotic or bipolar illness. The doubled relative risk reported here is concerning enough to warrant preventive counseling, yet the absolute risk remains modest for most users, and we cannot yet reliably predict which individuals are most susceptible. In clinical practice, a practical approach involves screening adolescents for personal or family psychiatric history before cannabis exposure, educating patients and families about this risk during sensitive periods, and maintaining heightened vigilance for early psychiatric symptoms in young users, while avoiding both dismissiveness and catastrophizing about cannabis use.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
